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a b s t r a c t
Response to environmental chemicals can vary widely among individuals and between population groups. In
human health risk assessment, data on susceptibility can be utilized by deriving risk levels based on a study of a
susceptible population and/or an uncertainty factor may be applied to account for the lack of information about
susceptibility. Deﬁning genetic susceptibility in response to environmental chemicals across human populations
is an area of interest in the NAS' new paradigm of toxicity pathway-based risk assessment. Data from highthroughput/high content (HT/HC), including -omics (e.g., genomics, transcriptomics, proteomics, metabolomics)
technologies, have been integral to the identiﬁcation and characterization of drug target and disease loci, and
have been successfully utilized to inform the mechanism of action for numerous environmental chemicals. Largescale population genotyping studies may help to characterize levels of variability across human populations at
identiﬁed target loci implicated in response to environmental chemicals. By combining mechanistic data for a
given environmental chemical with next generation sequencing data that provides human population variation
information, one can begin to characterize differential susceptibility due to genetic variability to environmental
chemicals within and across genetically heterogeneous human populations. The integration of such data sources
will be informative to human health risk assessment.
© 2011 Published by Elsevier Inc.

Introduction
Differential response to an environmental chemical exposure is due
to interactions between heredity and environment. Here we deﬁne
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susceptibility as the increased likelihood of an adverse effect in relation
to a human subpopulation factor such as life stage, demographic feature,
or genetic characteristic (EPA, 2005). Multiple intrinsic and extrinsic
susceptibility factors, including age, sex, ethnicity, nutrition status, and
lifestyle, contribute to human variability in biological response to
environmental agents. Because of these multiple interacting factors, the
identiﬁcation of causal factors responsible for the variable response for
even a single environmental agent is often unclear given the available
human data, and underlines the need for a better mechanistic
understanding of the risk factors that result in variable response to
environmental chemicals in humans.
When available, information on human genetic variation can be
used in human health risk assessment qualitatively and/or quantitatively to characterize variability and susceptibility differences in
response to a chemical exposure. For example, available information
could be used to estimate a risk level based on a study of a susceptible
population, and/or contribute to the information and rationale for
selecting the uncertainty factor (UF), thereby accounting for uncertainty in susceptibility among human populations. One example of
accounting for intraspecies uncertainty, as well as other uncertainties
in risk assessment, is the Environmental Protection Agency's (EPA)
Integrated Risk Information System (IRIS). IRIS accounts for uncertainty in the risk assessment process by using various uncertainty (or
This article is a U.S. government work, and is not subject to copyright in the United States.
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variability) factors (UFs) (for further information, see http://www.epa.gov/iris/), including the intraspecies UF that is applied when there
is a lack of data about population susceptibility or uncharacterized
variation in chemical response among humans. Note that the
intraspecies UF is not speciﬁcally accounting for genetic differences,
but instead is accounting for all types of intraspecies differences that
could contribute to an increased susceptibility. Limitations to deﬁning
susceptibility within the current risk assessment approach can
include data gaps on human susceptibility (e.g., genetic susceptibility,
lack of understanding of the relationships among different susceptibility factors) for many chemicals and inconsistency in applying the
intraspecies uncertainty factor.
Two recent reports from the National Academy of Science (NAS),
Science and Decisions (National Research Council, 2009) and Toxicity
Testing in the 21st Century (National Research Council, 2007), are part of
a concerted effort to review and overhaul the current risk assessment
process, and thereby improve US EPA human health risk assessments.
These two NAS reports underscore two needs for improving toxicity
testing and risk assessment of environmental chemicals: 1) increasing
mechanistic information; and 2) characterizing human susceptibility.
Toxicity Testing in the 21st Century (National Research Council, 2007)
presents a future vision of a toxicity pathway-based toxicity testing that
measures effects on the mechanism of action as the underlying basis.
The goal is to develop an understanding of human biological mechanism
for environmental chemicals by using appropriate human in vitro
toxicity pathway-based assays, in combination with mechanistic
computational systems biology models. The methods to be utilized in
the new paradigm (National Research Council, 2007) have several
advantages over current assays used in risk assessment including
increased sensitivity and measurement of precursor effects, increased
number of chemicals with available toxicity data (based on increased
analysis efﬁciency, increased cost-effectiveness and decreased animal
use), and measurement of effects in humans thereby eliminating crossspecies extrapolation issues. Disadvantages include the limited availability of in vitro and in vivo extrapolation methods in humans (i.e.,
establishing valid assays with known causal relationships between
chemical exposure, in vitro response, and phenotypic outcome in
humans), and the lack of a concrete path forward to achieve the 21st
century pathway-based approach. One important component of the
NAS' strategic plan is “the use of toxicity pathways information in risk
assessment,” although bridging the gap between current in vivo toxicitybased to pathway-based approaches remains an unscripted challenge.
Science and Decisions (National Research Council, 2009) provides a
number of recommendations for the overall risk assessment process.
Regarding susceptibility, the report states that variability in human
susceptibility “has not received sufﬁcient or consistent attention…” and

recommends that uncertainty and variability be characterized and
communicated in the quantitative steps of EPA risk assessments.
To address the need to characterize human genetic susceptibility
for informing human health risk assessment, we suggest a general
approach for integrating two existing data sources: 1) mechanistic
data implicating chemical–gene targets and 2) population polymorphism data characterizing genes implicated in chemical target
pathways. In order to outline the approach of combining mechanistic
data with human polymorphism data to deﬁne human susceptibility,
in this article we review the latest genomic and informatic approaches
for chemical target identiﬁcation and characterization of mechanism
of action, and discuss how genotype data from dense sequencing
projects can be combined with mechanistic data to inform risk
assessment about human susceptibility to environmental chemicals.
Lastly, we discuss future needs and directions in light of the NAS'
recommendations for improving toxicity testing and using information about variability and susceptibility in human health risk
assessment of environmental chemicals.
Data source I: Chemical mechanistic information
One obstacle in moving toward a human pathway-based toxicity
testing paradigm is the obvious lack of mechanism of action (see Fig. 1)
data for humans. We currently have limited knowledge of the effects of
environmental chemicals on published molecular pathways and in
related human disease etiology, including knowledge of key events in
human toxicity (National Research Council, 2010). In addition, there is
little known about the relationship among events that result in toxicity
in humans, causal steps in the continuum between exposure and
pathway perturbation, and how differences at the individual or
population level manifest in disease. The identiﬁcation of potential
chemical targets is the ﬁrst step in elucidating key molecular
interactions that trigger alterations in toxicity (Krewski et al., 2010),
and is a major research priority. For a shift to toxicity pathway-based
risk assessment to be realized, there is a need to characterize human
toxicity pathways for multiple, integrated, and diverse biological
processes in humans. The identiﬁcation of the molecular targets in
humans that, when perturbed, deﬁne the key events in a pathway or
process that is implicated in a probable adverse outcome would be a
critical step forward in understanding chemical toxicity related
processes (Mortensen et al., 2010) and susceptibility in human disease.
Several systems-based approaches have recently been developed in
order to better understand chemical–gene effects, characterize mechanism of toxicity in various toxicological contexts, and identify the genetic
loci implicated in toxicity (Hamadeh et al., 2002a,b; Butcher et al., 2004;
Goh et al., 2007; Edwards and Preston, 2008; Davis et al., 2009; Linghu

Fig. 1. Illustration of mechanism of action. Black arrows indicate the sequence of events in mechanism of action. Purple arrows indicate potential steps in the continuum leading to
observable disease outcome in humans where susceptibility could inﬂuence the outcome. Mechanism of action is deﬁned here as all of the steps, including toxicodynamic (TD) and
toxicokinetic (TK), between chemical exposure and the ﬁnal outcome at the level of the whole organism. Variation within humans could affect the resulting outcome at any TD and/
or TK step(s), indicated by the different boxes (adapted from Eubanks, 1994; Guyton et al., 2008; Jayapal et al., 2010).
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et al., 2009; Wiegers et al., 2009). Fig. 2a–c illustrates how consolidation
of information on chemical–gene association can be extended to a
pathway-level understanding by identifying disrupted target loci
through empirical studies. The integration of available information on
chemical–gene-pathway–outcome relationships provides information
about the putative or established mechanism of action, where target loci
are identiﬁed (Fig. 2a,b). Differing information may be available for nonhuman animal species thus providing for or limiting the extrapolation of
pathway effects to humans. Further, the chemical may affect multiple,
distinct or overlapping biological pathways within a single species. The
association of chemical, gene, and pathway does not directly implicate a
perturbation of a gene in a pathway, but highlights where empirical
evidence supports an association. Similar to candidate disease gene
studies, this list of chemical target loci can be expanded based on
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inclusion of related loci or reduced based on loci thought to be in
chromosomal linkage with a candidate loci (Fig. 2b,c). Two principal
approaches, direct experimental methods and informatic integration, can
contribute to the elucidation of chemical molecular mechanism of action
as described in Fig. 2a–b. These methods and some considerations
involved in their applications are described below.
Direct experimental approaches
Both in vivo and in vitro direct experimental sources contribute to
understanding of chemical mechanism of toxicity and identiﬁcation of
genetic loci implicated in toxicity. In vivo model systems are the
backbone of current toxicology testing of environmental chemicals,
and data from in vivo animal experiments is often used in the current

Fig. 2. Overview of the proposed process for the genetic characterization of variable response to environmental chemicals. Horizontal arrows indicate manipulation of data at various
stages of analysis. a, b. Data Source I includes direct experimental data, associating chemical X with molecular target(s) (e.g., gene or protein), obtained from animal toxicology,
human epidemiology, or in vitro methods. Data sources for mechanistic information for chemical X can be obtained from publically available resources (Table 1). Mechanistic
information is illustrated using a pathway-based framework. Red and green boxes indicate genetic targets affected by chemical X, where only RED target modiﬁcation is associated
with chemical X and the adverse outcome. c. Candidate or target loci can be characterized for variation at the nucleotide level. d. Data Source II is human genetic data, at the
nucleotide level. SNP haplotypes can be constructed from SNPs of interest. Use of tagged SNPs (i.e., representative SNPs from a region of the genome with high linkage
disequilibrium) can be used to limit redundant information. There are currently insufﬁcient methods to infer function with conﬁdence and functional effect of particular SNPs may
not be known at this stage. e. Cases and controls for a particular adverse outcome can be illustrated in terms of observed haplotype frequencies using haplotype networks, deﬁning
susceptible haplotypes. Cases can be further classiﬁed based on population association to inform the risk assessor of susceptible group (haplotype network adapted from Mortensen,
2008; Mortensen et al., 2011). f. Following susceptibility haplotype identiﬁcation, conﬁrmatory studies of function may be needed. The effect of molecular variation on functional
phenotype can be assessed using clinical, epidemiological or computational inference-based methods like those listed in Table 2.

Please cite this article as: Mortensen, H.M., Euling, S.Y., Integrating mechanistic and polymorphism data to characterize human genetic
susceptibility for environmental chemical risk assessment in the 21st century, Toxicol. Appl. Pharmacol. (2011), doi:10.1016/j.taap.2011.01.015

4

H.M. Mortensen, S.Y. Euling / Toxicology and Applied Pharmacology xxx (2011) xxx–xxx

human health risk assessment paradigm. Animal models have long
been used in the discovery of novel candidate genes in disease studies
(LePage and Conlon, 2006). Many genes implicated in human disease
susceptibility have been characterized using a comparative approach
utilizing animal models of human disease (Moore, 1999; Young, 2001;
Phillips et al., 2002; Ewart-Toland and Balmain, 2004; Simmons,
2008). Conservation of function among organisms is pivotal to the use
of traditional toxicological testing assays (National Research Council,
2000), as well as the basis for most research into the genetics of
human complex traits and disease (Boguski, 2002). The biological
mechanisms known to be associated with disease were identiﬁed in
many cases because they were highly conserved across species.
Conversely, the disruption of function of conserved genetic elements
can potentially lead to radically different phenotypic outcomes in
different species (McGary et al., 2010). An example relevant to both
pharmacology and toxicology is the phylogenetically diverse nuclear
receptor (NR) peroxisome proliferator-activated receptor alpha
(PPARα). Nuclear receptors control transcription through binding to
promoter regions of DNA. PPARα, like other NRs, exhibits many of the
species differences in NR structure and function observed between
rodents and humans. Species differences in response to PPARα
agonists have been attributed to differences in sequence similarity in
the DNA response elements, differences in hepatic expression level
(i.e., high expression in rodents in comparison to humans in response
to many substrates), hepatic microRNA (miRNA) expression, and the
presence of PPAR splice variants in humans (Miller and Willson, 2001;
Klaunig et al., 2003; Gonzalez and Shah, 2008; Peters et al., 2005;

Peters et al., 2008). Molecular variation at this level may affect
differences in the downstream pathway, which manifest in disease in
one species but not necessarily another. Thus, one limitation to the
use of animal assays for identifying human toxicity pathways/
mechanisms of action is uncertainty about the human mode or
mechanism of toxicity, because the evolutionary conservation of a
biological process cannot necessarily be assumed.
In vitro methods that are used in the characterization of chemical
mechanism, including -omics methods, focus on understanding
complex systems (e.g., genes and proteins). These approaches
complement traditional in vivo approaches to target identiﬁcation
and elucidation of mechanism in humans. Through the integration of
-omics technologies, an analysis of changes at the molecular level for
multiple interacting systems (or at the level of the genome) becomes
feasible and may provide a means for predicting toxicity in less time
than performing classical toxicological studies (Butcher et al., 2004).
Analysis methods that contribute to deﬁning chemical mechanism of
action include, but are not limited to, microarrays that measure gene
or protein expression in different cells or tissues under various
conditions, high throughput screening (HTS) assays that include cellbased systems, and ex vivo tissue methods that do not require a
culture medium and allow experimentation in or on a tissue outside of
an organism in a simulated environment. Study design choices (e.g.,
dose, dose–response, duration of exposure, route of exposure,
developmental timing) are important to consider when utilizing
studies, in vitro and in vivo, that will contribute to a picture of a
chemical's mechanism of action for an outcome of interest. For

Table 1
Open source molecular toxicology resources and databases.
Resource

Description

URL

ACToR—Aggregated
Computational Toxicology
Resources
Array Express

Compiles publically available data collections on environmental chemicals, including
EPA in vivo guideline study results (ToxRefDB) and chemical activity data (ToxCast).

http://www.actor.epa.gov

Repository for functional genomic experiments, focused on expression studies,
data mining, comparison and analysis tools.
Data integration tool for integrating data relating to environmental health,
pharmacology, and toxicology.
Collection of genome-wide transcriptional expression data from cultured human
cells treated with bioactive small molecules.
Elucidates molecular mechanisms by which environmental chemicals affect
human disease.
Archive of human genetic association studies of complex diseases and disorders.

http://www.ebi.ac.uk/microarray-as/ae/

CEBS—Chemical Effects in
Biological Systems
Connectivity Map

CTD—Comparative
Toxicogenomic Database
GAD—Genetic Association
Database
GEO—Gene Expression Omnibus Repository for a wide range of high-throughput experimental data, with query and
analysis functionality.
GO—Gene Ontology
Describes gene products in terms of their associated biological processes, cellular
components and molecular functions in a species-independent manner.
GSEA—Gene Set Enrichment
Determines whether a set of genes shows concordant differences between two
Analysis
biological states or phenotypes.
KEGG—Kyoto Encyclopedia of
Integrated database resource consisting of 16 main databases, broadly categorized
Genes and Genomes
into systems information, genomic information, and chemical information.
Pathway Commons
Collection of publicly available pathways from multiple organisms.
pCEC—Proﬁles of Chemical Effects Stores and handles gene expression proﬁling information and the categorization of
on Cells
toxicity data, and separates chemicals into a variety groups by the type of inﬂuence.
Database of primary genotype and phenotype data, annotated gene variants and
PharmaGKB—The
Pharmacogenomics Knowledge gene–drug–disease relationships obtained from literature review. Also includes
summaries of important pharmacogenetic genes and drug pathways.
Base
Reactome
A curated knowledgebase of biological pathways.
Known and predicted protein–protein interaction database.
STRING—Search Tool for the
Retrieval of Interacting Genes/
Proteins
SuperToxic
Predicts the toxicity of compounds, informs potential targets in biochemical
pathways, and shows potential binding partners.
ToxExpress
Database of integrated toxicity-based gene expression and classic toxicology endpoints.
ToxRTool—Toxicological
Data Reliability
Assessment Tool
TOXNET—Toxicology Data
Network

Evaluates quality and reliability of in vivo and in vitro toxicological data.

Database of toxicology, hazardous chemicals, environmental health, and
toxic releases.

http://www.niehs.nih.gov/research/
resources/databases/cebs/index.cfm
http://www.broadinstitute.org/cmap/
http://www.ctd.mdibl.org/
http://www.geneticassociationdb.nih.gov/
http://www.ncbi.nlm.nih.gov/geo/
http://www.geneontology.org/
http://www.broadinstitute.org/gsea/
http://www.genome.jp/kegg/
http://www.pathwaycommons.org/pc/home.do
http://www.project.nies.go.jp/eCA/cgi-bin/
index.cgi
http://www.pharmgkb.org/

http://www.reactome.org/
http://www.string.embl.de

http://www.bioinformatics.charite.de/supertoxic/
http://www.genelogic.com/knowledge-suites/
toxexpress-program
http://www.ecvam.jrc.ec.europa.eu

http://www.toxnet.nlm.nih.gov/
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example, mechanistic information, for a chemical and a particular
developmental outcome, from toxicity studies that exposed during a
critical window of development may be more meaningful than adult
exposure studies.

information will allow for a greater understanding of system and
pathway level changes related to toxicity and subsequently for the
identiﬁcation and characterization of molecular factors that contribute to human susceptibility.

Informatic integration

Data source II: Sequencing projects to characterize human
variation

Multiple efforts have been initiated to consolidate diverse datasets
of chemical toxicity, gene expression, and pathway level biological
processes from in vitro animal and human data, and in vivo studies
when available (Table 1). Database and knowledgebase approaches,
integrating multiple data types, make it possible to look for
associations and use statistical methods to look for correlation
among the different data sources. Database sources differ in a number
of aspects, such as hand curated or automated (for discussion, see
Judson, 2010). It is clear that available data must be integrated to
come to an overall conclusion on the toxicity of a chemical, as well as
understand the mechanisms of chemical toxicity (Mattingly, 2009).
One example of a project that integrates toxicity data sources is the US
EPA web-based resource, the Aggregated Computational Toxicology
Resource (ACToR), which houses publicly available data on chemical
identity, structure, and physical properties (Judson et al., 2008, 2009).
ACToR also houses data from the ToxCast high throughput screening
program, with in vitro assay data proﬁles for what will soon be 1000
environmental chemicals (http://www.epa.gov/comptox/toxcast/, (Dix
et al., 2007), as well as in vivo toxicology data from ToxRefDB (Knudsen
et al., 2009; Martin et al., 2009a,b). Data consolidated within ACToR have
been used to create bioactivity proﬁles based on in vitro chemical response
data and machine learning predictive signatures to infer phenotypic
outcomes (Judson et al., 2010). Methods, such as these, can be used to
associate chemicals with gene targets that may be important in particular
in vivo phenotypic outcomes.
Data within ACToR have also been integrated with human gene,
pathway, disease, and drug target information from multiple data
sources, though not yet publicly available, for use in association
mapping and toxicity inference (Mortensen et al., 2009, 2010).
Association between chemical exposure, genes, and disease can be
used in the absence of mechanistic information in humans. The
systems biology approach advocated here ultimately utilizes the
association between drug or environmental chemical exposure and
disease, the human “phenotypic anchor,” in the absence of direct
evidence of mechanism of toxicity. A number of recent informatic
approaches implementing molecular networks have been developed
that tackle the problem of identifying putative toxicity pathways by
using gene enrichment, chemical and disease association, and drug
target endpoints (Goh et al., 2007; Gohlke et al., 2009; Linghu et al.,
2009; Mortensen et al., 2009, 2010; Patel et al., 2010). Though these
types of association methods are supported by empirical, often
curated, knowledge, the mechanisms of action are typically not well
known, making them most useful for prioritization efforts for further
testing and hypothesis generation.
For genetic susceptibility to environmental chemicals to be
characterized there is a broad need for a more detailed description,
beyond association and weight of evidence approaches, to understanding the mechanisms of toxicity. Efforts have begun to consolidate what is currently known about various chemical mechanisms of
action for both humans and other species into a useable database
platform that can be easily integrated with chemical data found
within ACToR (Mortensen and Judson, unpublished results). The novel
approach of Sone et al. (2010) integrates data from the TOXLINE and
IRIS databases to manually deﬁne putative mechanisms of action
categories. These authors plan to expand their mechanisms of action
classiﬁcation into a larger HEALS (Health Effects Alert System)
database (Sone, personal communication). Future efforts involving
the integration of diverse data types poses several challenges to the
ﬁeld of bioinformatics; however, the consolidation of mechanistic

Until recently genetic studies in humans were primarily focused
on one or a few candidate genes to investigate disease–gene
phenotype associations. This type of study surveys gene sequence
variation at candidate loci across multiple individuals or populations.
Genetic information related to candidate loci is consolidated into
haplotypes, or combinations of polymorphisms at the nucleotide level
(e.g., Single Nucleotide Polymorphisms (SNPs), Copy Number Variants (CNVs)) across an individual chromosome (refer to Fig. 2d). The
frequencies of individual variants are then compared between the
individuals representing cases and controls for a disease phenotype of
interest (Fig. 2e), or alternatively from populations or groups that
exhibit differing disease phenotypes. From this, the individual
haplotypes associated with a disease can be identiﬁed within and
between groups, identifying potentially susceptible or at risk populations. Further testing can conﬁrm the precise functional genetic
variant(s) responsible for an association with a disease phenotype
(Fig. 2f). The effect of particular molecular variants on functional
phenotype can be assessed using clinical (Tishkoff et al., 2007) and
molecular epidemiological-based methods (Spitz and Bondy, 2010),
and computational inference tools (see Table 2 for open source
functional inference tools).
Ideally, for a disease of interest, there is a priori information about the
genetic basis of the disease, based on conspicuous determinants
typically identiﬁed in genetic epidemiological studies. Classic successes
that have identiﬁed the genetic determinants of disease phenotypes
include Huntington's disease, Alzheimer's disease, and some forms of
breast cancer (Risch and Merikangas, 1996). In the past 10 years, the
explosion of genomic information, bioinformatics tools, and open access
to large datasets has revolutionized research on complex traits,
including common human diseases. With the sequencing of the
human genome and next-generation sequencing technologies, the
genetic variation responsible for common disease phenotypes can be
explored more readily. Large-scale studies of human genetic variation,
such as the International HapMap Consortium, have focused on the
identiﬁcation of the underlying genetic variation in and across human
populations, the structure of that variation across the genome, and its
link to phenotype. The implementation of dense sequencing data thus
far has been largely in characterizing disease risk and pharmaceutical
response. Other applications of the HapMap data have provided
information about human study design, population structure and
statistical issues (Clark et al., 2005; Clayton et al., 2005; Goldstein,
2009), the characterization of natural selection (Nielsen et al., 2005;
Voight et al., 2006; Sabeti et al., 2007), and the characterization of
regions of linkage and recombination (Myers et al., 2005; Weir et al.,
2005). However, inquiry into common diseases has paved the way for
similar approaches to understanding differential human response to
environmental chemicals. With identiﬁed chemical targets, it is possible
to characterize variation in chemical response, with the aim of
informing human genetic susceptibility to environmental chemicals.
Following the HapMap efforts, several other deep sequencing projects
have been initiated and have speciﬁc objectives with the potential to
increase our understanding of human susceptibility to environmental
chemicals (Table 2).
Identiﬁcation of the ‘Environmental Genome’
Shortly after the ﬁrst completed resequencing of the human
genome, a collaborative effort between the National Institute of
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Table 2
Open source sequence annotation resources and phenotype inference tools.
Resource

Description

URL

1000 Genomes—A Deep Catalog
of Human Genetic Variation
ANNOVAR

Extensive public catalog of human genetic variation, including
SNPs and structural variants, and their haplotype contexts.
Functional annotation of HT sequence data with reported SNPs
from dbSNP, MAF N 1% from the 1000 Genome Project, or
subset of non-synonymous SNPs with SIFT score N0.05.
Gathers genome annotation information from multiple web sites,
collates the information, and displays it to the user in a single view.
Public archive of genetic variation, within and across different
species, containing characterized and uncharacterized
molecular variations.
Resequencing of 600 environmentally relevant genes thought to
play a role in susceptibility to environmental exposures in a panel
of 95 individuals representing the ethnic diversity found in
the United States.
Identiﬁes functional elements in the human genome sequence.

http://www.1000genomes.org/page.php?page=data

Publicly available graphical display of the newly identiﬁed SNPs
discovered through resequencing environmentally responsive
genes (EGP).
Assigns biological meaning to a set of non-coding genomic regions
by analyzing the annotations of the nearby genes.

http://www.genome.utah.edu/genesnps/

DAS—Distributed Annotation
System
dbSNP—Single Nucleotide
Database
EGP—Environmental
Genome Project

ENCODE—Encyclopedia of
DNA Elements
GeneSNPs Database

GREAT—Genomic Regions
Enrichment of Annotations
Tool
NHGRI GWAS Catalog
PolyPhen— Polymorphism
Phenotyping
Seattle SNPs

SIFT—Sorting Intolerant From
Tolerant
SNPnexus

Online catalog of GWAS publications that assay at least 100,000
SNPs; SNP-trait associations are indicated.
Predicts impact of an amino acid substitution on the structure
and function of a human protein using physical and comparative
(species homology) considerations.
Focused on identifying, genotyping, and modeling the associations
between SNPs in candidate genes and pathways that underlie
inﬂammatory responses in humans.
Predicts whether an amino acid substitution affects protein function
based on sequence homology and the physical properties of
amino acids.
Database designed to simplify and assist in the selection of
functionally relevant SNPs for large-scale genotyping studies of
multifactorial disorders.

Environmental Health Sciences (NIEHS) and the University of
Washington, the Environmental Genome Project (EGP) (Wilson and
Olden, 2004), was formed with the goal of implementing sequencing
technology to identify loci that contribute greater than average to
human susceptibility to environmental agents. An initial list of
environmentally responsive genes was identiﬁed, and gene targets
were selected for testing including loci implicated in DNA repair, cell
cycle control, drug metabolism, apoptosis, and cell differentiation and
signal transduction mechanisms. Systematic resequencing of these
genes was conducted in 95 human individuals from the polymorphism discovery resource (PDR) panel (Collins et al., 1998) that
represents the ethnic diversity present in the US. During phases 1 and
2 of this study, the EGP identiﬁed 92,486 SNP variants within 647
environmentally responsive candidate genes. Based on the hypothesis
that individuals with functionally signiﬁcant polymorphisms within
environmentally responsive gene regions may be particularly susceptible to genotoxic environmental agents, SNPs were selected for
population screening across both coding and non-coding regions of
these loci (Livingston et al., 2004). These data are publicly available
and housed in the GeneSNPs database (Table 2). In 2006, HapMap and
NCBI dbSNP updates were added to the GeneSNPs database, allowing
extension of the data to include validated genotypes and calculate
population speciﬁc haplotypes. Most studies that have analyzed data
from this important GeneSNPs database have focused on human
population genetics (e.g., changes in allele frequencies associated
with evolutionary processes such as natural selection, genetic drift,
mutation and gene ﬂow) rather than individual or population level
susceptibility across the genome (Gutenkunst et al., 2009; Ionita-Laza
et al., 2009; Lohmueller et al., 2010). The EGP has also been used to
validate other extensive human genome sequencing projects (Nick-
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http://www.snp-nexus.org/index.html

erson, personal communication) such as the 1000 Genomes Project
(Table 2). Because these data include environmentally responsive
genes, many of which are the targets of environmental agents or
implicated in biological processes involving chemical response, these
data could be useful in establishing baseline levels of variation across
human population groups for the ‘environmental response genome’.
Predicting functional consequences
Over 64 million distinct genetic variants are currently available in
the public domain, for multiple organisms including Homo sapiens
(dbSNP, build 131, see Table 1). However, only a small fraction of
these variants have been characterized in terms of their function,
occurrence in relevant populations (allele frequency and population
variation), or association with a phenotype or disease. The HapMap
Project has contributed to much of our current understanding of
underlying genetic variation in diverse humans populations and has
elucidated many of the variants associated with common disease
phenotypes (e.g., diabetes, obesity, breast cancer (Manolio and
Collins, 2009)). SNP variants, and more recently structural variation
(Eichler et al., 2007), have been investigated to understand the
pattern and nature of differences within the human genome, and their
functional effect.
The primary goal for genetic association studies is to identify the
functional variants associated with a phenotype of interest. Prioritization using gene and protein network properties has also been
informative in the identiﬁcation and selection of candidate disease
genes (Goh et al., 2007; Chen et al., 2009; Linghu et al., 2009; Nitsch
et al., 2010), and similar network methods have been described to
identify and rank order potential chemical target loci to investigate
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based on biological relationship (Mortensen et al., 2010). When the
mechanism of action is not well-characterized in humans, network
methods are useful in identifying loci related to a phenotype or
adverse outcome by using a chemical–gene association approach, as
described previously (see Fig. 2a–c). With a list of identiﬁed chemical
targets and a comprehensive catalogue of common variants in the
human population, the researcher is then faced with the question of
how to most effectively identify potentially causative susceptibility
variants. One general approach for identifying informative SNPs is to
compare correlation among SNPs of similar frequency (referred to as
linkage disequilibrium). Additionally, in looking for functional effects
of genetic variants, exons, regulatory regions, and conserved noncoding regions (CNS) among species are obvious regions to scan for
functional polymorphisms.
Studies of the heritability of gene expression indicate an
abundance of cis- regulatory variation in the human genome and
lack of trans- effects, suggesting that regulatory variation may be the
primary effect contributing to phenotypic variation in humans
(Kudaravalli et al., 2009) as well as a target of positive natural
selection (Kudaravalli et al., 2009). Whether variants of functional
signiﬁcance map to exon regions and near transcription start sites
(TSS) only, or exist within intronic regions has been an area of
contention. Stranger et al. (2007) found that the vast majority of
detected cis- regulatory effects map very close to the TSS, and
additionally note that these regions are enriched for regions that are
highly conserved (between species), suggesting that most of the large
effect variants will be in genic and immediate intergenic regions.
When a region of interest is identiﬁed, there is concern that SNP
characterization in publically available data may not be dense enough
to discover all functional variants. A recent study by Ionita-Laza et al.
(2009) addressed this issue by asking how many variants are left
undiscovered following dense sequencing of the human genome.
These authors compared three genetic discovery projects (i.e., NIEHS
SNPs, Seattle SNPs, and the ENCODE data (Table 2)), and found that
only a relatively small sample number of individuals (~150) is
sufﬁcient to identify 80% of the variants with a frequency of at least
0.1% (the frequency which deﬁnes a SNP), and that to discover all
variants requires a larger population sample size (~3000 individuals).
This is consistent with the ﬁnding that the population sample size
necessary to accurately survey a susceptibility allele (i.e., a gene
variant associated with a particular phenotype of interest) will
depend on the assumptions of how the allele and its effect vary
across subpopulations (Pritchard and Donnelly, 2001). Interestingly
and relevant to human health risk assessment, the analysis of IonitaLaza et al. (2009) indicates that environmental response genes show a
much greater diversity compared with the average genome. This was
observed to be especially true for African populations (Ionita-Laza
et al., 2009), which are known to be more genetically and
phenotypically diverse on average, compared to non-African groups
(European or Asian), as a result of having a longer evolutionary
history, as well as having experienced extensive variation in climate,
diet and exposure to infectious disease (Campbell and Tishkoff, 2008;
Tishkoff et al., 2009).
Use of human mechanistic and polymorphism data in
characterization of genetic susceptibility for environmental chemicals
The value of the consolidation and integration of the two data
types outlined here is that together these data can provide
information about potential genetic susceptibility across human
populations, contributing to what is known of differential human
response to environmental chemicals. We identiﬁed two chemicals
for which research has made use of both the available mechanistic and
human susceptibility information.
Benzene is one example of a chemical with an abundance of both
human mechanistic and genetic susceptibility data. Further, ongoing
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toxicogenomic studies to identify additional mechanisms and susceptibility factors are underway as part of a systems biology approach
to studying benzene (Zhang et al., 2010). Information on genetic
susceptibility to benzene exposure provides a complex picture of
multiple modes of action and human susceptibility genes identiﬁed in
both TK and TD steps of the mechanism of action, with some
polymorphisms conferring protective phenotypes and others increasing susceptibility in response to benzene exposure. Differences in
susceptibility to benzene hematotoxicity were established in several
studies of Chinese workers (Rothman et al., 1997; Wan et al., 2002;
Lan et al., 2009). Rothman et al. (1997) identiﬁed individuals with
both rapid CYP2E1 activity (conferring high rates of metabolism to
benzene oxide) and two copies of the mutant NQ01 alleles (conferring
low detoxiﬁcation activity). These CYP2E1-NQ01 haplotypes were
observed to have a statistically signiﬁcant increased risk of benzene
poisoning compared to controls (i.e., individuals with a slow CYP2E1
activity and two wild-type NQ01 alleles). Later studies indicate a
combined effect of three loci in benzene poisoning, NQO1, CYP2E1,
and GSTT1, as well as modifying lifestyle factors such as smoking and
alcohol consumption (Wan et al., 2002). TD differences in susceptibility to benzene have also been characterized. Polymorphisms in
genes involved in DNA repair and genomic maintenance have been
identiﬁed as associated with risk of benzene-induced hematotoxicity
(Lan et al., 2009). At least one of the genes, NQ01, has effects on
multiple pathways leading to both TK and TD differences, presumably
by impacting other pathways such as stabilizing p53 and microtubule
maintenance (Ross and Zhou, 2010). Recent systems biology
approaches to the study of benzene that focus on genomic screens
for candidate genes related to benzene exposure should further clarify
the interactions among benzene toxicity, susceptibility genes, mRNA
and DNA methylation (Zhang et al., 2010). Additionally, a case study
has been recently initiated to explore how to further utilize the more
recent benzene genomic and polymorphism data in risk assessment as
part of the NexGen EPA project (Sonawane, personal communication;
Ginsberg et al., 2009).
The study of Fry et al. (2008) builds on previous studies of variation
in transcription proﬁles in human lymphoblastoid cells derived from
healthy individuals (Cheung et al., 2005; Stranger et al., 2005; Dixon
et al., 2007). These authors ask what inﬂuence the observed variation
has on the response to environmental and chemotherapeutic agents,
speciﬁcally the DNA alkylating agent MNNG. Fry et al. (2008)
examined differentially expressed genes in human lymphoblastoid
cells, previously identiﬁed through microarray studies (Sabeti et al.,
2007). Using the PDR test population of 24 cell lines of diverse ancestry
(Collins et al., 1998), Fry et al. (2008) identiﬁed 48 of the differentially
expressed genes that were predictive (with 94% accuracy) of
differences in cellular sensitivity to MNNG. Response to MNNG, and
other environmental alkylating agents, has been characterized across
many species, and pathways that inﬂuence the associated DNA repair
mechanism are thought to be well-conserved. They found that
transcripts with high MNNG sensitivity are enriched for a common
regulatory factor, Oct-1, known to respond to DNA alkylation damage
(Zhao et al., 2000), as well as proteins associated with tumorigenesis.
The study ﬁndings contribute to our understanding of the interindividual differences in the mechanism of DNA damage response.
However, one limitation of the study of Fry et al. (2008) is that
variation at the level of the individual cell line compared to variation
within or between population groups was not addressed, probably due
to their use of a subset of the larger PDR panel (24 of 450) that does not
comprise a global population set. The study of Fry et al. (2008)
represents the only application of a human population diversity panel
to the characterization of chemical response and their approach can be
applied to other human outcomes. Future studies that include
characterization of variants associated with chemical sensitivity to
MNNG in human populations would aid in understanding how
variation between individuals corresponds to population level
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variation. Although these two excellent research examples share many
of the goals and data sources put forth in the current proposal, they
both have speciﬁc data availability limitations.
Conclusions
Currently, there is no single resource that integrates chemical
mechanistic data with human polymorphism data to allow for
identiﬁcation of gene targets in humans. Here we propose that
human genetic susceptibility information useful to human health risk
assessment could be gained by integrating these two existing data
sources. While the integration of these types of data for environmental chemicals is one area that begs for exploration, the challenge of
how to integrate systems biology concepts with interindividual and
population variation data has been noted (Zanger, 2010). One
recommended need is a web-based database including gene–
chemical targets with identiﬁed human susceptibility polymorphism
data from a global population panel for estimating population risk and
characterizing genetic susceptibility on a whole genome scale.
However, there are a number of outstanding issues, reviewed
below, to realizing this proposed approach and some potential next
steps in utilizing genomic data to inform human genetic susceptibility.
First, in order to utilize human genetic susceptibility information
of this nature, it is important to understand the mechanism(s) of
action of a toxicant, at the level of the molecular factors involved in
each biological process (Data Source I; Fig. 2a,b), as well as the
potential interactions among processes. One obvious data gap is in
complete mechanism of action information, including multiple modes
of action and interacting pathways under different conditions,
operating in the human. Further, use of the approach presented
could be signiﬁcantly improved with the organization and consolidation of mechanistic information related to human toxic response and
association with disease outcome. However, the approach presented
does not require a complete understanding of chemical mechanism of
action, where all targets and affected pathways have been identiﬁed.
Rather, one can utilize the available mechanistic data as a starting
point in what we and other authors (Andersen et al., 2010; Daston and
Naciff, 2010; Watanabe et al., 2011) have described as an iterative
process. For example, even information of a proposed or hypothesized
mode of action can suggest a biological process, where genes of
interest can then be identiﬁed and expanded upon by including all
available pathway information. Human SNP data, when available, can
improve our understanding of the mechanism of action by characterizing gene regions of interest (e.g., gene and protein structure,
linkage disequilibrium, and non-synonymous amino acid changes),
further elucidating variants that can then be tested for their
relationship to functional changes. Finally, the observation of
individual or population variation at SNPs found to be informative
to mechanism could contribute information about variation in
response. Other molecular mechanisms and processes related to
genotype–phenotype (e.g., epigenetic changes such as DNA methylation, chromatin remodeling) are just beginning to be interrogated in
humans. Understanding the complexity of human biology at a
mechanistic level is certainly the research challenge of this century,
for which the success of the 21st century paradigm for toxicity testing
and risk assessment depends heavily.
Secondly, one of the challenges of making effective use of genetic
and genomic data in risk assessment, and toxicological applications in
general, is in our ability to identify the biologically important genetic
variants for each toxic response phenotype (e.g., to associate
phenotype with genotype) (Data Source II; Fig. 2f). Usage of publically
available data in the inference of human variability at loci and
surrounding regions implicated in chemical response is one approach
to characterizing existing variation. The consolidation of this
information will reduce the number of technical aspects involved in
target identiﬁcation and selection by identifying what is known of

chemical susceptibility loci across the genome, identifying and
excluding conserved variants that are functionally signiﬁcant but
that are not variable among individuals and populations. Further,
understanding of genomic function outside of the typical promotergene structure is limited, and therefore, decision rules for selecting
functionally relevant SNPs is an area that should improve in the
coming years, as is indicated by the recent increase in functional
annotation and phenotype inference tools (Table 2). Additionally, the
present discussion does not include the new application of NGS to
RNAseq, which has the ability to directly assess the effect of genetic
variants on phenotypic response to chemical exposure.
A third issue concerns study design and study comparability
within and across the two data sources. For example, the identiﬁcation of human genetic susceptibility risk factors for environmental
agents, where multiple, complex combinations of genetic and
environmental factors may contribute to any single phenotype, will
require large sample sizes to achieve the power necessary for
association mapping of variants. Statistical, speciﬁcally power, issues
in association mapping of complex disease variants have also been
problematic, and may underline the importance of environmental
contribution to phenotype. However, recent approaches to more
directly understand the environmental contribution to common
disease, or chemical response, like the Environment-Wide Association
Study (EWAS) (Patel et al., 2010) are promising. Similar to GWAS, the
beneﬁts of EWAS is in hypothesis generation, where association
between environmental factors and disease can propose tests for
correlation and suggest genetic targets for further study. The
combination of GWAS and other -omics approaches with EWAS will
be useful and will allow for simultaneous assessment of genetic
variability of key environmental factors with disease on a global scale,
facilitating the characterization of disease causation and estimated
risk that has not yet been possible with genome-wide scans alone. The
EWAS approach is aligned with what proponents of the ‘exposome’
(Wild, 2005) are advocating as a means to improve understanding of
environmental contribution, speciﬁcally, the relation of exposure
effects to human disease. Technological advances should, in the near
future, make linking exposure to changes at the molecular level
feasible (Arnaud, 2010), and this information would certainly inform
risk at the individual and population level.
The information that would be generated from applying this approach
would be useful to current human health risk assessment practices as well.
In the current risk assessment paradigm, information on human genetic
susceptibility, when available, is incorporated qualitatively and/or
quantitatively. For example, the genetic susceptibility information
concerning benzene from several genetic studies, available at the time
that the assessment was undertaken, was incorporated qualitatively into
the 2003 IRIS benzene assessment (US Environmental Protection Agency,
2002) by describing polymorphisms in metabolic enzymes and the
frequencies of those polymorphisms in speciﬁc populations. With the NAS
envisioned, new risk assessment paradigm of toxicity pathway perturbation, information about mechanism at the level of genes, pathways, and
interactions among pathways will continue to become more available for
chemicals, where data are currently lacking. There are currently only a
small number of pharmaceuticals with relatively well-characterized
mechanisms or modes of action (Klein et al., 2001). For example,
chemicals that act on xenobiotic metabolizing enzymes, such as
cytochrome P450 enzymes, have a well-deﬁned mode of action and
have been associated with deﬁned human polymorphisms (e.g., CYP2E1;
Ginsberg et al., 2009). Thus, this class of chemicals would be excellent
candidates for testing this approach. Additionally, differential susceptibility in response to benzene exposure is an example that could be better
characterized by including recent human polymorphism data for the
gene and pathway perturbations identiﬁed after benzene exposure, from
a representative global panel. The approach, outlined herein, of
combining next generation sequencing data with mechanistic data for
environmental chemicals will inform the relationship between human
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toxicity pathways, genetic susceptibility, and disease progression
(including precursor events) and this information could be applied to
risk assessment.
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